Phase 2 study of dasatinib in Chinese patients with chronic myeloid leukemia (CML) in chronic phase (CP) or advanced phase who are resistant to or intolerant of imatinib (IM)

被引：0
|
作者：
Wang, Jianxiang [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ]
Huang, Xiaojun
Hu, Jianda
Li, Jianyong
Jin, Jie
Meng, Fanyi
Shen, Zhixiang
Liu, Ting
Wu, Depei
Wang, Jianmin
机构：
[1] Chinese Acad Med Sci, Inst Hematol, Beijing, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Beijing, Peoples R China
[3] Peking Univ, Inst Hematol, Beijing, Peoples R China
[4] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[5] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China
[6] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China
[7] Jiangsu Prov Hosp, Suzhou, Peoples R China
[8] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[9] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
[10] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Shanghai, Peoples R China
[11] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[12] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[13] Second Mil Med Univ, Changhai Hosp, Shanghai, Peoples R China
来源：
LEUKEMIA & LYMPHOMA | 2013年 / 54卷
关键词：
CML; dasatinib; imatinib-resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3
引用
收藏
页码：3 / +
页数：3
相关论文
共 50 条
  • [1] Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).
    Khoury, H. J.
    Kim, D.
    Zaritskey, A.
    Apperley, J.
    Besson, N.
    Volkert, A.
    Wang, J.
    Arkin, S.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] BUDGET IMPACT ANALYSIS OF DASATINIB IN IMATINIB-RESISTANT OR-INTOLERANT PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) IN THE CHINESE SETTING
    Wu, B.
    VALUE IN HEALTH, 2016, 19 (07) : A881 - A881
  • [3] A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
    Rosti, G.
    le Coutre, P.
    Bhalla, K.
    Giles, F.
    Ossenkoppele, G.
    Hochhaus, A.
    Gattermann, N.
    Haque, A.
    Weitzman, A.
    Baccarani, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] DASATINIB TREATMENT OF IMATINIB-RESISTANT AND IMATINIB-INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN A CHRONIC PHASE
    Vinogradova, O. Yu.
    Turkina, A. G.
    Vorontsova, A. V.
    Chelysheva, E. Yu.
    Gusarova, G. A.
    Kuznetsov, S. V.
    Goryacheva, S. R.
    Sokolova, M. A.
    Abakumov, E. M.
    Stakhina, O. V.
    Domracheva, E. V.
    Misyurin, A. V.
    Khoroshko, N. D.
    TERAPEVTICHESKII ARKHIV, 2009, 81 (07) : 41 - 46
  • [5] Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 'START-C' Study.
    Hochhaus, A.
    Kantarjian, H.
    Baccarani, M.
    Cervantes, F.
    Facon, T.
    Goldberg, S.
    Erben, P.
    Countouriotis, A.
    Ezzedine, R.
    Druker, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 339S - 339S
  • [6] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC)
    Giles, Francis J.
    le Coutre, Phillip
    Bhalla, Kapil N.
    Ossenkoppele, Gert
    Alimena, Giuliana
    Haque, Ariful
    Gallagher, Neil
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 311A - 312A
  • [7] A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib
    Giles, F. J.
    le Coutre, P.
    Bhalla, K.
    Rosti, G.
    Ossenkoppele, G.
    Alimena, G.
    Weitzman, A.
    Zheng, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).
    Khoury, Hanna Jean
    Mauro, Michael J.
    Matloub, Yousif
    Chen, Tai-Tsang
    Bahceci, Erkut
    Deininger, Michael
    BLOOD, 2009, 114 (22) : 463 - 464
  • [9] DASATINIB LACK OF CROSS INTOLERANCE TO IMATINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (CML-CP) WHO ARE INTOLERANT TO IMATINIB - A RETROSPECTIVE SAFETY ANALYSIS
    Guilhot, E.
    Goldberg, S. L.
    Stone, R. M.
    Mauro, M.
    Matloub, Y.
    Chen, T. T.
    Khoury, H. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 51 - 51
  • [10] A phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (Pts) with chronic myeloid leukemia (CML) in chronic phase (CP) who failed IM therapy.
    Cortes, J
    Garcia-Manero, G
    O'Brien, S
    Hernandez, I
    Rackoff, W
    Faderl, S
    Thomas, D
    Ferrajoli, A
    Talpaz, M
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 289A - 289A
12345